期刊文献+

15例原发性巨球蛋白血症免疫表型和治疗分析 被引量:4

下载PDF
导出
摘要 目的:探讨原发性巨球蛋白血症(WM)的临床特点。方法:回顾性分析15例患者免疫表型及治疗。结果:临床表现多样性,免疫表型CD20+占75%,CD19+CD22+占50%,CD38+37.5%。15例接受治疗患者有11例部分缓解,其中加用沙利度胺的全部都获部分缓解。结论:传统的诊断WM方法不够完善,免疫表型能够更进一步明确诊断。在治疗方面可考虑在化疗并血浆置换的基础上,使用沙利度胺来联合治疗。
出处 《临床血液学杂志》 CAS 2006年第1期37-38,共2页 Journal of Clinical Hematology
  • 相关文献

参考文献9

  • 1Garcia-Sanz R, Montoto S, Torrequebrada A, et al.Waldenstrom's macroglobulinemia., presenting features and outcome in a series with 217 cases. Br J Haematol,2001, 115:575-582.
  • 2Stephem M, Baird E. Plasma cell neoplasms., general considerations [A]. In: Williams J W. Hematology[M]. 5th ed. New York: Mc Graw-Hill Book Company, 1995. 1097-1097.
  • 3Owen R G, Barrans S L, Richards S J, et al. Waldenstrom's macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol, 2001, 116:420-428.
  • 4Remstein E D, Hanson C A, Kyle R A, et al. Dispite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia. Is consistently composed of ceils along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol, 2003, 30:182-186.
  • 5王金凯,张金巧,吴薇薇,孟剑波,仝永会,李玉所.血浆置换联合化疗治疗原发性巨球蛋白血症[J].临床血液学杂志,2001,14(2):91-91. 被引量:2
  • 6刘丽辉,武永吉.反应停治疗多发性骨髓瘤的机制及临床应用[J].临床血液学杂志,2002,15(3):138-139. 被引量:31
  • 7Dimopoulos M A, Zomas A M, Viniou Z A, et al.Treatment of Waldenstrom's macroglobulinemia with thalidomide. Clin Oncol, 2001, 19:3596-3601.
  • 8Treon S P, Raje N, Anderson K C. Immunotherapeutic strategies for the treatment of plasma cell malignancies.Semin Oncol, 2000, 27:598-613.
  • 9Martino R, Shah A, Romcro P, et al. Allogenenic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia. Bone Marrow Transplant, 1999,23:747-749.

二级参考文献10

  • 1阮林海,谢毅,郑敏华.血浆置换治疗原发性巨球蛋白血症的临床研究[J].临床血液学杂志,1995,8(1):13-15. 被引量:8
  • 2王金凯,魏平.血浆置换结合CLM联合化疗治疗难治性类风湿性关节炎的应用研究[J].实用医学杂志,1997,13(7):429-431. 被引量:3
  • 3Bellamy W,List A,Grogan T.Expression of VEGF and its receptors in myeloma.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
  • 4Tosi P,Ronconi S,Zamagni E,et al.Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation[].Haematologica.2001
  • 5Rajkumar S V,Leong T,Roche P C,et al.Prognostic value of bone marrow angiogensis in multiple myeloma[].Clinical Cancer Research.2000
  • 6Schreiber S,Ackermann J,Obermair A,et al.Multiple myeloma with eletion of chromosome 13q is characterized by ineased bone marrow neovascularization[].British Journal of Haematology.2000
  • 7Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide: focus on palliative care[].Drugs.2000
  • 8Celgene.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
  • 9Faith E D,Noopur R,Teru H,et al.Thalidomide and immunmodulatory derivatives augment natral killer cell cytotoxicity in multiple myeloma[].Blood.2001
  • 10Rajkumar S V,Witzig T E.A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma[].Cancer Treatment Reviews.2000

共引文献31

同被引文献41

引证文献4

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部